-
Cytokeratin 17
Cytokeratin 17
- 中文名称：
- Cytokeratin 17
- 英文名称：
- Cytokeratin 17
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA59288
- 规格：
- 5 Slides|0.1 mL (Concentrate)|3 mL (RTU)|7 mL (RTU)|0.5 mL (Concentrate)
- 保存建议：
- Store at 2 to 8 degree C in the dark.
- 货期：
- 6-8周
- 来源宿主：
- Mouse
- 反应种属：
- Human, Rat, Goat and Pig
- 应用：
- IHC (Immunohistochemistry)
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:Monoclonal
同型:IgG2a/K
克隆号:N/A
特异性:N/A
纯度:N/A
形式：Cytokeratin 17 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
浓度：N/A
- 说明书：
Cytokeratin 17 (CK 17) is a Type I cytokeratin with a MW of 46 kD found sometimes in association with Cytokeratin 7. Cytokeratin 17 is found in nail beds, hair follicles, sebaceous glands, and other epidermal appendages. Mutations in the gene encoding this protein lead to Jackson-Lawler type Pachyonychia Congenita and Steatocystoma Multiplex.Cytokeratin 17 antibody has been used to distinguish immature Cervical Squamous Metaplasia from High Grade Cervical Intraepithelial Neoplasia (CIN III). Anti-CK 17 also labels myoepithelial cells in the benign breast tissue. CK 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK 5&6, p63, and SOX-2 for differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK 17. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK 17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.
